Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator, providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, the company saves time and money in getting drugs to patients.

Its flagship offering is Translational Pharmaceutics®, a fully integrated drug development and clinical testing platform, that reduces timelines and costs, getting new medicines to patients faster, by integrating drug substance, drug product, and clinical testing activities.

In July  2019, Permira led a group of private investors that acquired a majority stake in Quotient.

The company has more than 1300 employees, and seven manufacturing and clinical facilities in the UK and the US.